Nebenwirkungsmanagement von Immuncheckpoint-Inhibitor-Therapien

 

 Buy Article Permissions and Reprints

Abstract

Immunotherapy with checkpoint inhibitors – monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) or the programmed death-1 receptor (PD-1) and its ligand PD-L1 – is now standard of care in the treatment of patients with various tumor types. Therefore, the management of immune-related adverse events (irAEs) has become part of clinical routine.

Immune-related adverse events can involve any organ or tissue. They can occur very early within days or weeks after initiation of treatment but can also occur months into treatment and after termination of treatment. Newest data suggest that irAEs can occur until 2 years after stopping therapy.

Immune-related adverse events are graded according to Common Terminology Criteria for Adverse Events (CTCAE). Treatment ranges from local or symptomatic treatment, systemic application of corticosteroids to other immunosuppressive agents according to severity.

The following article seeks to give a general approach to the management of patients receiving immunotherapy and experiencing irAEs including prevention, diagnostics and treatment.

Publication History

Article published online:
26 August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 Sharpe AH. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev 2017; 276: 5-8 DOI: 10.1111/imr.12531.
  CrossrefPubMedGoogle Scholar
• 2 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264 DOI: 10.1038/nrc3239.
  CrossrefPubMedGoogle Scholar
• 3 Reck M, Rodriguez-Abreu D, Robinson AG. et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016; 375: 1823-1833 DOI: 10.1056/NEJMoa1606774.
  CrossrefPubMedGoogle Scholar
• 4 Robert C, Long GV, Brady B. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330 DOI: 10.1056/NEJMoa1412082.
  CrossrefPubMedGoogle Scholar
• 5 U.S. Department of Health and Human Services. CTCAE Version 5.0. Im Internet (Stand: 10.06.2021): https://ctep.cancer.gov
  PubMedGoogle Scholar
• 6 Johnson DB, Balko JM, Compton ML. et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 2016; 375: 1749-1755 DOI: 10.1056/NEJMoa1609214.
  CrossrefPubMedGoogle Scholar
• 7 Haanen J, Carbonnel F, Robert C. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv119-iv142 DOI: 10.1093/annonc/mdx225.
  CrossrefPubMedGoogle Scholar
• 8 Owen CN, Bai X, Quah T. et al. Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma. Ann Oncol 2021; 32 (07) 917-925 DOI: 10.1016/j.annonc.2021.03.204.
  CrossrefPubMedGoogle Scholar
• 9 Heinzerling L, Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol 2017; 29: 136-144 DOI: 10.1097/CCO.0000000000000358.
  CrossrefPubMedGoogle Scholar
• 10 Weber JS, Hodi FS, Wolchok JD. et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol 2017; 35: 785-792 DOI: 10.1200/JCO.2015.66.1389.
  CrossrefPubMedGoogle Scholar
• 11 Wolchok JD, Neyns B, Linette G. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164 DOI: 10.1016/S1470-2045(09)70334-1.
  CrossrefPubMedGoogle Scholar
• 12 Hodi FS, O'Day SJ, McDermott DF. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723 DOI: 10.1056/NEJMoa1003466.
  CrossrefPubMedGoogle Scholar
• 13 Larkin J, Chiarion-Sileni V, Gonzalez R. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 23-34 DOI: 10.1056/NEJMoa1504030.
  CrossrefPubMedGoogle Scholar
• 14 Wolchok JD, Chiarion-Sileni V, Gonzalez R. et al Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377: 1345-1356 DOI: 10.1056/NEJMoa1709684.
  CrossrefPubMedGoogle Scholar
• 15 Heinzerling L, de Toni EN, Schett G. et al. Checkpoint Inhibitors. Dtsch Arztebl Int 2019; 116: 119-126 DOI: 10.3238/arztebl.2019.0119.
  CrossrefPubMedGoogle Scholar
• 16 Champiat S, Lambotte O, Barreau E. et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559-574 DOI: 10.1093/annonc/mdv623.
  CrossrefPubMedGoogle Scholar
• 17 Postow MA, Hellmann MD. Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018; 378: 1165 DOI: 10.1056/NEJMc1801663.
  CrossrefPubMedGoogle Scholar
• 18 Ijaz A, Khan AY, Malik SU. et al. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. Biol Blood Marrow Transplant 2019; 25: 94-99 DOI: 10.1016/j.bbmt.2018.08.028.
  CrossrefPubMedGoogle Scholar
• 19 Brahmer JR, Lacchetti C, Schneider BJ. et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768 DOI: 10.1200/JCO.2017.77.6385.
  CrossrefPubMedGoogle Scholar
• 20 Thompson JA, Schneider BJ, Brahmer J. et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw 2020; 18: 230-241 DOI: 10.6004/jnccn.2020.0012.
  CrossrefPubMedGoogle Scholar
• 21 Santini FC, Rizvi H, Plodkowski AJ. et al. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res 2018; 3: 1093-1099 DOI: 10.1158/2326-6066.CIR-17-0755.
  CrossrefPubMedGoogle Scholar
• 22 Kahler KC, Hassel JC, Heinzerling L. et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges 2016; 14: 662-681 DOI: 10.1111/ddg.13047.
  CrossrefPubMedGoogle Scholar
• 23 Hassel JC, Heinzerling L, Aberle J. et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 2017; 57: 36-49 DOI: 10.1016/j.ctrv.2017.05.003.
  CrossrefPubMedGoogle Scholar
• 24 Puzanov I, Diab A, Abdallah K. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5: 95 DOI: 10.1186/s40425-017-0300-z.
  CrossrefPubMedGoogle Scholar
• 25 Fachinfo-Service. Fachinformation Nivolumab Stand 04/2021. Im Internet: https://www.fachinfo.de
  PubMedGoogle Scholar
• 26 Fachinfo-Service. Fachinformation Pembrolizumab Stand 03/2021. Im Internet: https://www.fachinfo.de
  PubMedGoogle Scholar
• 27 Fachinfo-Service. Fachinformation Avelumab Stand 01/2021. Im Internet: https://www.fachinfo.de
  PubMedGoogle Scholar